Physician profile
John Lee Abraham
NPI 1760595136
$766.62
in general payments reported to CMS, 2019-2025
15 companies · $48.57 in 2025
The $48.57 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.91 · 2020: $43.94 · 2021: $156 · 2022: $118 · 2023: $181 · 2024: $125 · 2025: $48.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $353.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $176.06 | 2021-2022 | |
| Abbott Laboratories | $113.41 | 2022-2023 | Freestyle Libre |
| Arcutis Biotherapeutics, INC. | $111.26 | 2024 | Zoryve |
| Amarin Pharma, INC. | $94.91 | 2019 | |
| Abbvie INC. | $85.48 | 2022-2023 | Botox |
| Lilly USA, LLC | $40.92 | 2022-2023 | Mounjaro, Trulicity |
| Allergan, INC. | $29.18 | 2020 | |
| Boston Scientific Corporation | $19.84 | 2021 | |
| Galderma Laboratories, L.P. | $18.85 | 2023 | |
| Dexcom, INC. | $18.00 | 2025 | Dexcom G6 Transmitter |
| Ardelyx, INC. | $15.31 | 2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $15.26 | 2025 | Trintellix |
| Astrazeneca Pharmaceuticals Lp | $14.76 | 2020 | |
| Pfizer INC. | $13.38 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.